2025
NVOS Novo Integrated Sciences Inc
Go

Health Care : Biotechnology | Small Cap Value

Celldex Therapeutics, Inc. is a biopharmaceutical company. It is focused on developing therapeutic monoclonal and bispecific antibodies that address diseases for which available treatments are inadequate. Its drug candidates include antibody-based therapeutics, which has the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. Its bispecific platform includes CDX-585 and CDX-527. CDX-585 combines its active PD-1 blockade and anti-ILT4 blockade to prevent immunosuppressive signals in T cells and myeloid cells, respectively. Its other programs include CDX-1140, a fully human agonist monoclonal antibody targeted to CD40.

The symbol you entered, AVAN, changed to CLDX.

Premarket

Last Trade: Delayed
$35.51

Change Since Close Change Since Close Postmarket extended hours change is based on the last price at the end of the regular hours period. Premarket extended hours change is based on the day's regular session close.: 0.54 (1.54%)

Bid: --

Ask: --

B/A Size: --

Market Hours

Closing Price: $34.97

Day's Change: 0.00 (0.00%)

Bid close: --

Ask close: --

B/A Size: --

Day's High: --

Day's Low: --

Volume (Light) Volume: 428 10-day average volume: 354,443: 428

Latest Earnings Met Consensus (Q1 ending 03/2023)				Next Earnings Announcement
Q1 Non-GAAP earnings GAAP vs. Non-GAAP Earnings TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced May 4, 2023	-$0.62	Q1 Estimate range of 5 analysts	-$0.66 to -$0.60	Q2 Earnings will announce	(Unconfirmed) August 7, 2023

Quarterly Earnings History and Estimates

Show high-low estimates

Display:

NoneShow growth rate from year to yearCompare same period to previous yearUpdate Cancel

CLDX's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.

Premarket

Change Since Close

Market Hours

GAAP vs. Non-GAAP Earnings

Quarterly Earnings History and Estimates